Lantern Q2 2026 slides: operating loss drops 25%, LP-300 data strengthens

On August 14, 2026, Lantern Pharma (LTRN) released its Q2 2026 financial results, revealing a 25% decrease in operating losses and promising clinical breakthroughs for its lead oncology candidate LP-300. The company's stock fell 3.23% to $2.55 following the announcement. Despite a wider net loss, Lantern Pharma's operating expenses reduced significantly due to a 42% decline in research and development spending to $1.8 million.

However, non-cash warrant expenses widened the net loss by $3.6 million. The company's balance sheet showed a decrease in cash reserves from $10.1 million to $7.4 million. Lantern Pharma emphasized the need for additional funding, aiming to pursue capital raises and collaborations. The Q2 results highlighted LP-300's progress in non-small cell lung cancer trials, with extended treatment duration benefiting certain patients.

Additionally, Lantern Pharma secured regulatory approval for its investigational product LP-184 in a Phase 1b/2 bladder cancer trial in Denmark. The company's strategic separation of Open-Medicine AI into a standalone entity was also announced, positioning itself to capitalize on the growing AI drug discovery market.